combined controls. Five of eight experimental mice demonstrated no tumor growth at 
21 days post challenge, though one animal subsequently developed a tumor. One of 
eight animal's tumor challenge grew slower than the controls, while two experimental 
mice grew tumors at similar rates as the controls. Table II shows the results of both the 
kbalb and 205 tumor models expressed as a percentage of tumor rejection after 
rechallenge of mice which had rejected a TK positive tumor with approximately 50% of 
the mice rejecting tumor rechallenges. 
29 
Table II 
Tumor Total Reject. % Reject. 
kbalb 
8 mice 
4 mice 
50 
205 
28 mice 
13 mice 
44 
IL-1 studies in vitro indicate that this molecule is critical in the process of antigen 
activation of T cells. The activated T cells can then produce the spectrum of regulatory 
cytokines which lead to antibody production and cellular immunity. It appears then that 
IL-1 is a cytokine which acts early in the cascade of events leading to an immune 
response, and it is therefore attractive to explore the use of this cytokine in an adjuvant 
role to enhance the immune response. It has been found that several adjuvants 
function through production of IL-1. The agents lentinan (26), lipopolysaccharide (27), 
aluminum hydroxide (28), Ru 41.740 (29) (extract of k. pneumoniae ), and tuftsin (13) 
[588] 
Recombinant DNA Research, Volume 15 
